Introduction {#S1}
============

Single-nucleotide variant (SNV), also known as single-nucleotide polymorphism (SNP), is the variant of a single nucleotide that occurs at a specific genomic position. It is the most common type of genetic variants, which has long been confirmed in various loci of the genome ([@B41]). In the past few decades, genetic variants have been typically used to dissect complex human disorders through research on candidate genes, particularly genome-wide association study (GWAS), an observational study of the genome-wide set of genetic variants in different individuals, which is performed to identify whether any variant is associated with the phenotypes. As a representative of a large-scale variant analysis, it has provided an approach to identifying potential genetic variant loci associated with heterogeneous disorders, including cancer susceptibility ([@B17]). With the development of emerging technologies, such as microarray-based genotyping and high-throughput next-generation sequencing, it offers a novel avenue for the clinical application of genetic variants ([@B26]). As might be expected, the role of genetic variants in understanding the pathogenesis of diseases, therapeutic response, and even ultimately personalized medicine will be indispensable in the near future. Based on the implementation of the International HapMap Project and the 1000 Genomes Project, great breakthroughs have been achieved in the research field of genetic variants, particularly focusing on some variants of protein-coding genes ([@B41]; [@B21]). However, genetic variants, especially SNVs, not only occur to protein-coding sequences, but many of them also fall within non-coding regions or the intergenic regions between two genes. For instance, a considerable genetic component has been confirmed to be involved in the susceptibility of various cancers; the genomic contexts of cancer-associated SNVs (SNPs) have been analyzed within a comprehensive GWAS catalog. Of these risk variants, less than 10% are mapped in protein-coding regions, whereas most of them are located in the intronic or intergenic regions ([Figure 1A](#F1){ref-type="fig"}), it brings forward the issue of these non-coding loci and their importance role in cancer research ([@B34]).

![**(A)** Genomic distribution of single-nucleotide variants in cancers; a majority of cancer-associated single-nucleotide variants (SNVs) \[single-nucleotide polymorphisms (SNPs)\] are found in the intergenic or intronic regions, and only small numbers are located in protein-coding regions of the human genome. **(B)** Classification of long non-coding RNA (lncRNA) transcripts; long intergenic non-protein coding RNA (lincRNA) is a major subtype of lncRNA.](fcell-08-00347-g001){#F1}

The Human Genome Project (HGP) has determined the whole sequence of nucleotide base pairs that compose the human genome and initially provided approximately 20,000 proteins that could serve as therapeutic targets ([@B85]). Subsequent large-scale annotation efforts, such as the Encyclopedia of DNA Elements (ENCODE) project, surprisingly, have identified hundreds of thousands of non-coding RNAs, which were previously regarded as "junk DNA" ([@B82]). Among them, a great quantity of long non-coding RNAs (lncRNAs) are transcribed in mammalian genomes. Based on their locations and characteristics, lncRNAs can be placed into five broad categories: (1) intergenic, (2) antisense, (3) sense, (4) intronic, and (5) overlapping ([@B72]; [@B13]). Thereinto, long/large intergenic non-protein coding RNAs (lincRNAs), which are located within the genomic interval between two coding genes, are the major subtypes of lncRNAs accounting for approximately 63% ([Figure 1B](#F1){ref-type="fig"}). Compared with other lncRNAs, molecules for which we know next to nothing about, lincRNAs are generally unexplored and have yet to be elucidated. About half of these lincRNAs are transcribed from the vicinity (\<10 kb) of protein-coding loci and more likely to be involved in *cis*-regulatory of the expression level of adjacent genes; other transcripts that are well away from an adjacent gene seem to have little chance of *cis*-regulatory within the nearby region. Although they rarely form triplexes within double-stranded DNA owing to their poor complementarity to sequences elsewhere within the genome, these lincRNAs often act as *trans*-regulatory players within some ribonucleoprotein complexes ([@B84]). LincRNAs may have crucial roles in various disorders and cellular models *via* multiple mechanisms. Alterations in the levels of lincRNA expression have been linked to the occurrence of various disorders, such as cancers; they may act as tumor suppressors or proto-oncogenes ([@B40]). Currently, advances in high-throughput RNA sequencing and computing approaches allow for an unparalleled analysis of transcriptomes. Of the diverse kinds of RNA transcripts, lincRNAs are attractive as they can be found out from the existing RNA-seq datasets through available bioinformatics methods ([@B4]).

According to recent reports from the ENCODE project, thousands and thousands of variant loci are present in the non-coding regions of the human genome, and total number continues to increase ([@B76]). Generally, genetic variants, such as SNVs, which occur to the non-coding loci, are more frequently than in conservative protein-coding genes regions. A large number of GWAS-identified SNVs loci reside in the regions that encode lincRNAs, indicating that these variants of lincRNAs may play a crucial role in the susceptibility of diseases. More than three quarters of disease-associated genetic variants are remarkably overlapped in promoter or enhancer regions, suggesting that SNVs may serve as an important player in the regulation of transcript levels ([@B34]). Therefore, identification of such variant loci and elucidation of their biological functions would be of profound significance in understanding the etiology of disorders and in promoting novel approaches for the diagnosis, prevention, and treatment of disorder.

Long Intergenic Non-Protein Coding RNA Variants and Disease Susceptibility {#S2}
==========================================================================

As a matter of fact, the occurrence of complex diseases (e.g., cancer) is related to multiple factors, including genetic, environmental, and lifestyle. Among them, genetic factors are of particular interest, just as GWASs and next-generation sequencing studies have greatly broadened the understanding of genetic variants that confer risk of diseases. Numerous genetic variants in lincRNA regions have been determined to be associated with the susceptibility of heterogeneous diseases, especially multiple types of cancer. Herein, we reviewed some lincRNAs that encompass disease or trait-associated variants ([Tables 1](#T1){ref-type="table"},[2](#T2){ref-type="table"}).

###### 

Overviews of trait-associated variants on the chr8q24 locus.

  LincRNA    Trait-associated variants   Diseases                                                                Position             References
  ---------- --------------------------- ----------------------------------------------------------------------- -------------------- --------------------------------
  *CASC8*    rs378854                    Adiposity                                                               Intron               [@B66]
             rs10505477                  Colorectal, gastric, and lung cancers                                   Intron               [@B60]; [@B37]
  *CASC19*   rs138042437                 Prostate cancer                                                         Intron               [@B81]
  *CCAT1*    rs6983267                   Colorectal cancer, endometrial carcinoma                                Enhancer             [@B47]; [@B102]
  *CCAT2*    rs6983267                   Prostate, breast, colon, and colorectal cancers; myeloid malignancies   Exon                 [@B99]; [@B83]; [@B59]; [@B77]
  *PCAT1*    rs7463708                   Prostate cancer                                                         Enhancer             [@B27]
             rs10086908                  Prostate cancer                                                         Promoter             [@B27]
  *PRNCR1*   rs1456315, rs7463708        Prostate cancer                                                         Exon                 [@B10]
             rs13252298, rs1456315       Colorectal cancer                                                       Exon                 [@B55]
             rs183373024                 Prostate cancer                                                         Exon                 [@B81]
  *PVT1*     rs13281615                  Breast cancer                                                           Promoter             [@B101]
             rs2720709, rs2648875        End-stage renal disease (ESRD)                                          Intron, intron       [@B31]
             rs378854                    Prostate cancer                                                         Promoter             [@B64]
             rs13255292, rs4733601       Diffuse large B cell lymphoma                                           Intron, downstream   [@B5]

LincRNA, long intergenic non-protein coding RNA.

###### 

Overviews of other lincRNAs encompassing trait-associated variants.

  LincRNA          Trait-associated variants   Diseases                                                                                                                Position       References
  ---------------- --------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------- -----------------------
  *CASC16*         rs3803662                   Breast cancer, lung cancer                                                                                              Exon           [@B69]
  *CASC15*         rs6939340                   Neuroblastoma                                                                                                           Intron         [@B62]
  *GAS5*           rs145204276                 Hepatocellular carcinoma (HCC), colorectal, and gastric cancers                                                         Promoter       [@B80]; [@B56]
  *H19*            rs217727                    Coronary artery disease, type 2 diabetes                                                                                Exon           [@B19]
                   rs2067051                   Pneumoconiosis, coronary artery disease                                                                                 Exon           [@B19]; [@B94]
                   rs2107425                   Ovarian and breast cancers, hypertrophic cardiomyopathy                                                                 Intron         [@B9]
                   rs2839698                   HCC, bladder, colorectal, and gastric cancer                                                                            Exon           [@B86]; [@B9]; [@B98]
  *HULC*           rs7763881, rs1041279        HCC                                                                                                                     Intron         [@B88]
  *LINC00673*      rs11655237                  Pancreatic cancer                                                                                                       Exon           [@B103]
  *LINC00951*      rs11752942                  Esophageal squamous cell carcinoma (ESCC)                                                                               Exon           [@B92]
  *LOC105378318*   rs1875147                   Leprosy                                                                                                                 Intron         [@B15]
  *MALAT1*         rs619586                    Pulmonary arterial hypertension (PAH), coronary atherosclerotic and congenital heart disease (CAD/CHD), breast cancer   Exon           [@B105]; [@B57]
                   rs1194338                   Colorectal cancer                                                                                                       Promoter       [@B58]
                   rs4102217                   HCC                                                                                                                     Promoter       [@B89]
  *MEG3*           rs941576, rs34552516        Type 1 diabetes (T1D)                                                                                                   Intron         [@B87]; [@B91]
  *MIAT*           rs2331291                   Myocardial infarction                                                                                                   Intron         [@B43]
                   rs1894720                   Paranoid schizophrenia                                                                                                  Exon           [@B74]
  *PCGEM1*         rs6434568, rs16834898       Prostate cancer                                                                                                         Intron         [@B96]
  *PCAT19*         rs11672691                  Prostate cancer                                                                                                         Promoter       [@B18]
  *PTCSC2*         rs965513                    Papillary thyroid carcinoma (PTC)                                                                                       Intron         [@B33]
  *PTCSC3*         rs944289                    PTC, large-vessel ischemic stroke                                                                                       Promoter       [@B44]; [@B53]
  *TDRG1*          rs8506                      ESCC, gastric cancer                                                                                                    Exon           [@B30]
  *TINCR*          rs2288947, rs8105637        Colorectal cancer, gastric cancer                                                                                       Exon, intron   [@B104]

LincRNA, long intergenic non-protein coding RNA.

Long Intergenic Non-protein Coding RNA Variants on the chr8q24 Locus {#S2.SS1}
--------------------------------------------------------------------

Genome-wide association studies have pointed to the chr8q24 genomic locus as a hotspot for cancer-associated variants owing to the large density, more strength, and high allele frequency of these variants ([@B99]; [@B83]). Even though chromosome 8q24 has been considered as a "gene desert" region owing to the absence of functionally annotated genes, with the only notable exception of the frequently amplified *MYC* (a proto-oncogene involved in tumorigenesis) ([@B10]). Surprisingly, large-scale studies have revealed that several lincRNAs are transcribed from the chr8q24 locus, such as *CCAT1* ([@B47]), *CCAT2* ([@B59]), *PVT1* ([@B31]), *PCAT1* ([@B27]), and *PRNCR1* ([@B55]); all of these encompass multiple cancer-associated variants. For instance, lincRNA *CCAT2* (Colon Cancer-Associated Transcript 2, also termed *LINC00873*), a transcript spanning SNV rs6983267, is associated with an increased risk for prostate, breast, colon, and colorectal cancers ([@B99]; [@B83]; [@B59]). *CCAT2* is overexpressed in various types of cancers and may contribute to tumor growth, metastasis, and chromosomal instability by increasing MYC expression ([@B59]). LincRNA *PRNCR1* has been reported to be involved in prostate carcinogenesis and may play an oncogene role *via* modulating the androgen receptor ([@B10]), *PRNCR1* variants, especially rs1456315, are associated with the susceptibility of prostate and colorectal cancers ([@B55]; [@B81]). Through an integrative analysis of the lncRNA transcriptome and GWAS data, [@B27] have identified a prostate cancer-associated transcript *PCAT1* and 10 risk loci on the chr8q24.21, including *PCAT1* variants rs10086908 and rs7463708, which are significantly associated with prostate cancer susceptibility. As for *PVT1* (also termed *LINC00079*), a GWAS analysis has identified that its variants rs13255292 and rs4733601 are associated with the susceptibility of diffuse large B cell lymphoma ([@B5]). Other independent SNVs (e.g., rs2720709 and rs2648875), which are mapped on *PVT1*, especially contributes to the development of end-stage renal disease (ESRD) in patients with type 2 diabetes ([@B31]). A recent meta-analysis has summarized the relationship between two common variants (rs10505477 and rs7837328) in the intronic region of *CASC8* (*LINC00860*) at 8q24 locus with the risk of cancers ([@B12]), including colorectal, gastric, and lung cancers ([@B60]; [@B37]). Another intronic loci rs378854 is related to adiposity in the individuals of African ancestry ([@B66]).

Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNA H19 Locus {#S2.SS2}
------------------------------------------------------------------------------

The *H19* (also termed *LINC00008*) is located in chromosome 11p15.5, a paternally imprinted onco-fetal gene, which is typically down-regulated in adult tissues but can be overexpressed in multiple types of solid cancer. LincRNA *H19* expression is closely related to tumor growth, metastasis, recurrence, and clinical prognosis ([@B20]). *H19* variants are involved in the susceptibility of multiple diseases. A meta-analysis study has indicated that variant T allele of rs2107425 is correlated with a decreased risk of developing cancers (e.g., breast, ovarian, lung, and bladder cancers) ([@B9]; [@B93]), whereas variant rs2839698 is associated with an increased risk of digestive cancers (colorectal and gastric cancers) *via* up-regulating *H19* expression; of note, there is no significant association observed between rs217727 variant and cancers susceptibility ([@B9]). However, in other reports, *H19* rs217727 has been linked to the risk of hepatocellular carcinoma (HCC) ([@B20]), oral squamous cell carcinoma (OSCC), and bladder cancer in the Chinese population ([@B28]). For coronary artery disease (CAD), the T variant of rs217727 is associated with an increased risk, whereas rs2067051 A variant is linked to a decreased risk ([@B19]). *H19* rs217727, but not rs2107425 variant, is associated with susceptibility of women with preeclampsia (PE) ([@B32]). Additionally, maternally transmitted fetal *H19* variants (e.g., rs217727, rs2071094, and rs10732516), along with paternal *IGF2* variants, are independently correlated with the placental DNA methylation levels ([@B63]) and birth weight of newborns ([@B70]).

Single-Nucleotide Variant in *MALAT1* and *MIAT* Regions {#S2.SS3}
--------------------------------------------------------

LincRNA *MALAT1* (metastasis-associated lung adenocarcinoma transcript 1, also termed *LINC00047*) has rs619586 A \> G variant, which is significantly associated with the susceptibility of pulmonary arterial hypertension (PAH), and the carriers with variant G genotypes have a decreased PAH risk ([@B105]). Recent study has suggested that rs619586 AG/GG genotypes could reduce the risks of coronary atherosclerotic heart disease and congenital heart disease (CHD) by regulating *MALAT1* expression ([@B57]). Another report has showed that *MALAT1* is overexpressed in colorectal cancers and that SNV rs1194338 mapping to its promoter region is significantly associated with a decreased risk of colorectal cancer ([@B58]). Moreover, the large-scale case--control association studies have identified a novel myocardial infarction-associated transcript, *MIAT* (also termed *LINC00066*), which encompasses rs2331291, and other variants confer the susceptibility of myocardial infarction ([@B43]). As a component of the nuclear matrix, *MIAT* is mainly expressed in neurons, [@B74] have reported that SNV rs1894720 is correlated with paranoid schizophrenia susceptibility, and MIAT may contribute to the pathogenesis of schizophrenia.

Other Long Intergenic Non-protein Coding RNA Variants in Human Cancers {#S2.SS4}
----------------------------------------------------------------------

In addition to the above lincRNA molecules, recent studies have identified many other cancer-associated variants within lincRNA regions. For example, the tissue differentiation-inducing non-protein coding RNA (*TINCR*), also termed *LINC00036*, is essential for somatic tissue differentiation and tumor progression ([@B50]). It has been demonstrated that two variants of *TINCR* (rs2288947 and rs8105637) are significantly correlated with the susceptibility and lymph node metastasis of colorectal cancer ([@B104]); the lincRNA *TINCR* rs2288947 G allele and rs8113645 A allele genotypes could reduce the risk of gastric cancer. *HULC*, an HCC up-regulated lncRNA, also termed *LINC00078*, and its variants (rs7763881 and rs1041279) are linked to the susceptibility of HCC ([@B88]). In thyroid carcinoma, several papillary thyroid carcinoma susceptibility candidates, such as *PTCSC2*, contain a risk-variant rs965513, and *PTCSC3* encompasses rs944289; two lincRNA expression levels are strongly down-regulated in thyroid carcinoma tissues ([@B44]; [@B33]). Additionally, GWAS analyses have identified five tag-SNVs, including rs944289 located in *PTCSC3*, are associated with large-vessel ischemic stroke ([@B53]). [@B96] have reported that a prostate cancer gene expression marker, *PCGEM1* (*LINC00071*), containing two risk-SNVs (rs6434568 C and rs16834898 A alleles) that are associated with a decreased risk of prostate cancer. Another prostate cancer risk-associated allele rs75823044 mapping to promoter of *LINC00676* is almost exclusively found in African ancestry populations ([@B11]). In a GWAS analysis, five common variants including rs3803662 on the exon of *CASC16* (*LINC00918*) have been identified to contribute to the susceptibility of lung and breast cancers ([@B69]). Furthermore, the colorectal cancer risk-SNV rs11776042 is located in the promoter of *LNC00964*, in which lincRNA is significantly decreased in colorectal cancer tissues ([@B8]). For tumor suppressor lncRNA *GAS5*, an insertion/deletion variant of rs145204276 is associated with the susceptibility of HCC ([@B80]) and colorectal and gastric cancers ([@B56]).

Other Disease-Associated Variants in Long Intergenic Non-protein Coding RNA Regions {#S2.SS5}
-----------------------------------------------------------------------------------

Except for cancer susceptibility, some lincRNA variants are found to be associated with the risk of other heterogeneous diseases. GWAS and expression quantitative trait locus (eQTL) analyses have identified a risk factor for pathological inflammatory responses of leprosy, SNV rs1875147, which is an eQTL variant for lincRNA *LOC105378318* located in chromosome 10p21.2 ([@B15]). Rautanen et al. have found a variant rs140817150 in the intron of *LOC107986770*, which may be correlated with bacteremia susceptibility in African children ([@B45]). A systematic analysis highlights some variant loci in lncRNA regions linked to cardiometabolic disorders; one of them, lincRNA *LOC157273* harboring rs4841132, is linked to the regulation of serum lipid cholesterol ([@B22]). [@B78] GWAS analysis has identified a major depressive disorder (MDD) risk-associated variant rs12526133, which resides in exon of *LINC01108*, in which lincRNA is overexpressed in patients with MDD. Moreover, the maternally expressed imprinted gene, *MEG3* (also termed *LINC00023*), containing variants rs941576 ([@B87]) and rs34552516 ([@B91]), which is found to be associated with susceptibility of type 1 diabetes. [@B67] comprehensive GWAS meta-analyses have reported an association of CAD susceptibility with several SNVs, such as rs1870634, which is located in the downstream of *LINC00841*, and its GG genotype is strongly linked to CAD risk and has a higher frequency in CAD patients.

Long Intergenic Non-Protein Coding RNA Variants and Clinicopathological Characteristics, Prognosis, and Treatment Response {#S3}
==========================================================================================================================

For Clinicopathological Characteristics and Prognosis {#S3.SS1}
-----------------------------------------------------

In addition to disease susceptibility, trait-associated SNVs are widely used for the indication of clinicopathological characteristics, prognosis, and treatment response ([@B25]). For example, with regard to a neuroblastoma-associated variant rs6939340, which is mapped on the intronic locus of lincRNA *CASC15* and *NBAT1*, neuroblastoma individuals with the risk alleles are more likely to have clinical aggressive presentation, including metastatic disease, tumor with *MYCN* amplification, and disease relapse ([@B62]). Two independent cohort studies have observed that risk-SNV rs2608053 of *PVT1* is correlated to the survival outcome of patients with classical Hodgkin lymphoma ([@B23]). For multiple sclerosis, several risk loci of *PVT1* may contribute to the prediction of an optimal response to treatment with glatiramer acetate ([@B51]). LincRNA *H19* variants have been found to increase the risk of ischemic strokes, and the up-regulated *H19* may induce cerebral ischemia reperfusion injury by activating autophagy ([@B90]). Recent studies have reported that *H19* rs2839698 variant may serve as an indicator for the increased risk and poor prognosis of HCC ([@B98]). Among individuals with coal workers' pneumoconiosis (CWP), carriers of *H19* rs2067051 CT/TT genotypes are associated with a decreased risk; *H19* rs2067051 may be a possible biomarker for CWP prevention ([@B94]). A case--control study has shown that lincRNA *MALAT1* variant rs4102217 is related to increased HCC risks; this SNV may be a potential predictor for the risk and prognosis of patients with HCC ([@B89]). Another *MALAT1* rs3200401 T allele has been found to confer better survival for patients with advanced lung adenocarcinoma ([@B90]). Furthermore, *TDRG1* (testis development related 1, also termed *LINC00532*) is overexpressed in esophageal squamous cell carcinoma (ESCC) tissues; the AA genotype of variant rs8506 is linked to an increased risk of ESCC; this risk allele may regulate TDRG1 expression by disrupting the sponge binding of miR-526b; high TDRG1 expression and rs8506 A allele variant may contribute to the advanced tumor--node--metastasis stage and poor survival for ESCC patients ([@B30]). Recent GWAS analyses have demonstrated that variant rs11672691 of *PCAT19* (*LINC01190*) on 19q13 is positively related to aggressive prostate cancer. Further cohort studies have confirmed the association of rs11672691 with clinical characteristics of aggressive disease, including high tumor stage, prostate-specific antigen (PSA) progression, and development of castration-resistant prostate cancer (CRPC). The risk GG genotype of rs11672691 is also associated with a poor prognosis for patients with prostate cancer ([@B18]). These results highlight the clinical potential of trait-associated SNV, which may serve as risk stratification markers for the management of cancer patients.

Indication of Treatment Response {#S3.SS2}
--------------------------------

Recent GWAS analyses have identified two common SNVs (rs4476990 and rs3802201), in which mapping to *MIR2052HG* may affect the recurrence risk of breast cancer patients treated with aromatase inhibitors. Expressions of *MIR2052HG* and estrogen receptor α (ERα, encoded by *ESR1* gene) are induced by aromatase inhibitors and estrogen in a variant-dependent manner. *MIR2052HG* could sustain the levels of ERα *via* promoting AKT/FOXO3-mediated *ESR1* transcription and limiting the ubiquitin-mediated ERα degradation. Its risk variant genotypes could enhance ERα binding to estrogen response elements and result in an alteration of response to aromatase inhibitors treatment for cancer patients ([@B42]). In the evaluation of adverse reaction for lung cancer patients receiving platinum-based chemotherapy, the variants *CASC8* rs10505477 ([@B37]) and *ANRIL* rs1333049 are correlated with overall toxicity, especially severe hematologic and gastrointestinal toxicity; lincRNA *MEG3* rs116907618 is correlated with severe gastrointestinal toxicity; these variants may be considered as biomarkers for the evaluation of platinum-based treatment ([@B25]). Moreover, the rs10505477 GG genotype of *CASC8* is also associated with tumor size, lymph node metastasis, and tumor--node--metastasis stage and may contribute to the survival for gastric cancers patients ([@B60]). In nasopharyngeal carcinoma (NPC), lncRNA *GAS5* variant rs2067079 is associated with an increased risk of severe myelosuppression and neutropenia, whereas rs6790 may decrease the incidence rate of toxic reactions induced by chemo-radiotherapy in NPC patients ([@B29]). Functional genomic studies have revealed that *GAS5* promoter encompassing SNV rs55829688 (T \> C), which up-regulates *GAS5* expression *via* interacting with transcription factor TP63, may aggravate myelosuppression and result in a poor prognosis for patients with acute myeloid leukemia (AML) ([@B97]). Additionally, GWAS analyses have identified that some genetic variants are correlated with the pharmacokinetics of psychotropic drugs, such as variant rs16935279 located in an intron of LINC01592; its C allele carriers have a lower metabolism rate for anti-epileptic drugs ([@B3]).

Long Intergenic Non-Protein Coding RNA Variants Regulate Gene Transcription {#S4}
===========================================================================

Genome-wide association studies have identified a lot of trait-associated variants, most of which reside in non-coding regions of the human genome. However, the specific functional mechanism of genetic variants still remains confused, which is one of the major challenges for post-GWAS research ([@B76]). The regulatory elements are mainly located within regions of non-coding DNA and play critical roles in the transcription of target genes. Emerging studies have showed that these regulatory elements can affect the expression of lincRNAs and other related genes *via* long-range chromatin interactions in a cell-type- or tissue-specific manner. Many genetic variants reside in the regulatory element regions of lincRNAs and may disrupt the interaction of transcription factors with a region containing SNVs ([Figures 2A,B](#F2){ref-type="fig"}). The mapping of SNVs to lincRNA regulatory regions (especially promoters and enhancers) may indicate a potential impact of these variants on the transcription of target genes ([@B26]).

![Graphical representations of the driving effect of variants \[single-nucleotide variants (SNVs)\] on long intergenic non-protein coding RNA (lincRNA) regions. **(A)** Genetic variants located in promoter may affect the binding of transcription factors and regulate the transcription of lincRNAs. **(B)** Genetic variants on enhancer affect the binding of transcription co-regulators and regulate lincRNA expression. **(C)** Genetic variants on intron may affect the process of splicing and stability of lincRNA conformation. **(D)** Genetic variants located in exons affect the lincRNA secondary structure, lincRNA stability, and interactive function. **(E)** Genetic variants on exons may affect the sponging of microRNAs (miRNAs).](fcell-08-00347-g002){#F2}

Single-Nucleotide Variants in Super-Enhancer Locus of *MYC* Gene {#S4.SS1}
----------------------------------------------------------------

Many genetic variants are located in the upstream of *MYC*, a gene desert on 8q24, which is related to the susceptibility of multiple cancers. Some observations, such as chromosome conformation capture (3C) assays, histone acetylation, and methylation marks analyses, have demonstrated that these regulatory regions containing SNVs may serve as enhancers for *MYC* gene in a tissue-specific manner. Functional investigations suggest that lincRNA *CCAT2* augments the binding of transcription factor (TCF7L2 or TCF4) to *MYC* promoter region, activates WNT signaling, and increases the expression of target genes, especially the *MYC* proto-oncogene ([@B71]; [@B59]). Although there is a disputable association between variant rs6983267 and *MYC* expression ([@B83]), its risk G alleles produce more *CCAT2* transcripts, which are exclusively retained in the nucleus. Interestingly, a risk-SNV rs6983267 also contributes to increased expression of *CCAT1* ([@B102]); an adjacent lincRNA of *CCAT2*, through affecting the long-range chromosomal interaction of *MYC* enhancer or *CCAT1* promoter, then results in a cell-cycle regulation and tumor development ([@B47]). [@B27] have reported that a prostate cancer risk-associated T allele of rs7463708 at lincRNA *PCAT1* exhibited enhancer activity, through modulating the binding of novel transcription factor ONECUT2 with a distal enhancer that loops to the *PCAT1* promoter; this process increases *PCAT1* expression upon prolonged androgen treatment and promotes prostate transformation. Moreover, another prostate cancer risk-SNV rs378854 G alleles are also found to increase the expression of *PVT1* oncogene by regulating an interaction of transcription factor YY1 with the promoters of *PVT1* or *MYC* genes ([@B64]). Similarly, the GG genotypes of rs13281615 increase *PVT1* transcription and promote cell proliferation in breast cancer ([@B101]). Overexpression of *PVT1* may contribute to high levels of MYC mRNA and protein, along with an increased copy number, eventually leading to tumorigenesis ([@B107]). These results demonstrate the association of genetic variants with lincRNA transcription, although further studies are needed to reveal the relationship of these SNVs and lincRNA*s* on chromosome 8q24 locus.

Single-Nucleotide Variants in Promoter Regions {#S4.SS2}
----------------------------------------------

Some SNVs reside in gene promoter regions and may influence the transcriptional expression of their target genes. Through an eQTL analysis of candidate genes and genetic variants in different tissues, an endometriosis risk-SNV rs3820282 is found to down-regulate *LINC00339* expression by affecting the activity of *LINC00339* promoter ([@B73]). [@B80] have reported that an indel variant rs145204276 in the promoter region of *GAS5* contributes to the up-regulation of *GAS5 via* affecting the methylation status of *GAS5* promoter and regulating its transcriptional activity, thereby bringing its proto-oncogene role into play. Furthermore, the variant rs944289 of *PTCSC3* is reported to reside in a binding site for CCAAT/enhancer binding proteins (C/EBPα/β); this variant may affect the activity of *PTCSC3* promoter and down-regulate its transcript, then resulting in an abnormal expression of downstream genes and the progression of papillary thyroid carcinoma ([@B44]).

Notably, a gene promoter region is likely to overlap with another super-enhancer locus, suggesting it that may have enhancer-like roles. In these interactions, lincRNA loci may serve as both target genes of its SNVs and the distal regulatory elements of other related genes. Integrative functional genomic and epigenomic analyses have identified that osteoporosis risk-associated SNV rs6426749 may act as a distal variant-specific enhancer and play a pivotal role in bone metabolism. Risk rs6426749 G alleles can affect the enhancer activity by binding to transcription factor TFAP2A; a thin process may increase transcription of *LINC00339* and modulate the expression of downstream gene *via* long-range chromatin loop formation in osteoblast cells ([@B7]). Recent studies have reported that prostate cancer risk-associated G allele of rs11672691 is associated with an increased expression of lincRNA *PCAT19* and oncogene CEACAM21; SNV rs11672691 is located in an enhancer element and may alter the binding site of its oncogenic transcription factor HOXA2. CRISPR/Cas9-mediated interference and activation assays have demonstrated that rs11672691 variant is involved in the regulation of its eQTL genes *PCAT19* and CEACAM21 expression and affects the cells' aggressive property in prostate cancers ([@B18]). In another alternative mechanism, risk variant rs11672691 is associated with the decreased levels of a short isoform of *PCAT19* (*PCAT19*-short) and increased levels of a long isoform (*PCAT19*-long). This risk SNV locus is bifunctional with both promoter and enhancer activity, which maps to a promoter of *PCAT19*-short and the third intron of *PCAT19*-long. Risk allele rs11672691 and its linkage disequilibrium SNV rs887391 may alter the binding profiles of transcription factors NKX3.1 and YY1, thereby elevating the abundance of *PCAT19*-long through promoter-enhancer switching. Ultimately, it gives rise to an increased formation of the HNRNPAB-*PCAT19*-long complex to activate a subset of cell-cycle genes and promote prostate cancer aggression ([@B38]).

Another causative *cis*-regulatory mechanism has been constructed *via* integrative genomic analyses; the breast cancer-associated variant rs4415084 is located in a GATA3-binding motif of *LINC02224*, which refers to the differential GATA3 binding and chromatin accessibility, thereby promoting the transcription of *LINC02224* and *MRPS30* genes ([@B100]). It is reasonable to postulate that the interactions of lincRNA, trait-associated variants, and regulatory factor may contribute to the development of specific disorders.

Single-Nucleotide Variants Affect the Biological Function of Long Intergenic Non-Protein Coding RNA {#S5}
===================================================================================================

Currently, genetic variants in potential lincRNA regions have attracted increasing interest; it has been established that many SNVs are associated with susceptibility of multiple diseases. It is evident that the expression and function of lincRNAs may be influenced by its SNVs in a cell-type- or tissue-specific manner. A comprehensive analysis has suggested that genetic variants in lincRNA regions also possibly affect the process of splicing and stability of lincRNA conformation, thereby leading to a modification of their interacting partners, as shown in [Figures 2C--E](#F2){ref-type="fig"} ([@B36]).

Effect of Single-Nucleotide Variants on the Role of Long Intergenic Non-protein Coding RNA CCAT2 {#S5.SS1}
------------------------------------------------------------------------------------------------

Several observations, such as eQTL and DNAase peak assays, indicate that genetic variants that occurred in exons of lincRNAs may change the lincRNA secondary structure, thereby affecting its stability, interactive properties, and regulatory functions ([@B46]). For example, lincRNA *CCAT2* could act as a scaffold or assembly platform and modulate the alternative splicing of glutaminase (GLS) pre-mRNA *via* directly binding to a Cleavage Factor I (CFIm) complex. However, SNV rs6983267 (G/T) may affect the interaction of CCAT2 with CFIm complex by changing lincRNA secondary structure and initiating a domino effect mechanism; this process leads to allele-specific reprogramming of cellular energy metabolism in colon cancers ([@B75]). Moreover, by using allele-specific *CCAT2* transgenic mice, recently, [@B77] have revealed that overexpression of *CCAT2* may lead to genomic instability and myeloid malignancies; the SNV rs6983267-specific RNA-editing induces the dysregulation of a genome-wide gene expression by down-regulating EZH2, a histone-lysine *N*-methyltransferase, which then results in the impairment of immune processes and development of myelodysplastic neoplasms *in vivo*. In another study, Sur IK and his colleagues have generated mice lacking a *myc* enhancer region spanning risk-SNV rs6983267; the mutant mice have not showed an overt phenotype but confer resistance to intestinal tumorigenesis induced by APC^*min\ mutation*^ ([@B79]). These studies indicate that cancer risk-associated variants identified from the human genome may also exert a functional effect for animals *in vivo*.

Effect of Single-Nucleotide Variants on the Long Intergenic Non-protein Coding RNA Secondary Structure {#S5.SS2}
------------------------------------------------------------------------------------------------------

It is worth noting that lincRNAs have a long average length and that their exon regions contain numerous trait-associated variants; significant alterations of lincRNA secondary structure may be caused by its SNVs on exon loci. Many variants such as *PRNCR1* (prostate cancer-associated non-coding RNA) are located in exon regions, for example, rs1456315 G/A; it has been predicted to affect the lincRNA secondary structure of *PRNCR1* ([@B10]) and then alter lincRNA stability and conformation, even giving rise to the modification of its interacting partners. [@B95] have also reported that SNV rs7958904 G/C in an exon region does not affect transcription activity of *HOTAIR*; however, in *in silico* analyses, it is shown to alter the RNA secondary structure of *HOTAIR*. These findings indicate that genetic variants, especially SNVs in exon loci, may play a different role *via* affecting the lincRNA structure.

Effect of Single-Nucleotide Variants on MicroRNA Binding {#S5.SS3}
--------------------------------------------------------

Not surprisingly, it has been documented that some microRNAs (miRNAs) can function in a non-canonical manner to regulate lincRNA expression levels or directly interact with lincRNA molecules. The competing endogenous RNA (ceRNA) is a mechanism that lncRNA could competitively bind or sponge miRNAs, such as ceRNA *MALAT1*; its exon locus contains a variant rs619586 A \> G, which can significantly up-regulate the expression of XBP1 (X box-binding protein 1) by sponging miR-214 and then suppressing the proliferation and migration of vascular endothelial cells *in vitro* ([@B105]). In another case, variant rs11752942 of *LINC00951* exon is linked to the susceptibility of ESCC; risk G alleles of rs11752942 may decrease the expression levels of *LINC00951 via* affecting the binding of miR-149-3p, thereby regulating cell proliferation and tumor growth ([@B92]). Intriguingly, recent studies have demonstrated that pancreatic cancer risk-SNV rs11655237 G \> A in the *LINC00673* exon region is likely to create a target site for miR-1231 binding and reduces the function of LINC00673 in an allele-specific manner. Down-regulation of LINC00673 may attenuate the interaction of PTPN11 with an E3 ubiquitin ligase PRPF19 and suppress the ubiquitin-mediated PTPN11 degradation; these processes enhance an oncogenic signaling whereas diminish STAT1-dependent anti-oncogenic signaling in cancer cells ([@B103]). These findings highlight the regulatory relationships of miRNAs with lincRNAs in a variant-specific manner and may offer a wider field for future research on lincRNA.

Approaches for Identifying Drivers {#S6}
==================================

As summarized above, genetic variants play a very significant role in the transcription and biological function of lincRNAs, contributing to various disease susceptibility, progression, prognosis, and treatment response. Genetic variants may act as a driving factor to affect the role of lincRNAs; just like a driver who drives a vehicle, analogously, lincRNA variants may vividly serve as a putative driver to regulate the lincRNA molecules.

Computational Approaches {#S6.SS1}
------------------------

Driver identification is a challenging task, owing to their complex and diverse modes of action and the inadequate understanding of non-coding regions; the computational prediction of non-coding drivers is even more challenging than that of protein-coding drivers. In addition, non-coding variants are more abundant than protein-coding genes; hence, the key variants with functional significance have to be distinguished from a larger set of passenger events ([@B46]). Currently, several online databases have been constructed to describe genomic variants in lncRNA regions, such as lincSNP, lncRNASNP2, and LncVar. More specifically, lincSNP 2.0 is an integrated database to identify and annotate disease-associated SNVs on human lincRNAs and their transcription factor binding sites ([@B68]). LncRNASNP2 is an updated database of comprehensive information about SNVs or mutations in human and mouse lncRNAs, as well as their impacts on lncRNA structure and potential function on miRNA binding ([@B65]). LncVar provides genetic variants associated with lncRNAs in multiple species and their effects on biological function of lncRNAs ([@B6]). Furthermore, a large number of GWAS analyses have successfully identified an array of genetic variants that are associated with various types of human disorders ([@B61]). Numerous public databases have been set out to provide a comprehensive description of genetic variants and GWAS data in the human genome with high impact ([@B21]). A brief overview of these databases with their key features and corresponding references is presented in [Table 3](#T3){ref-type="table"}.

###### 

Some databases that may be used for driver identification.

  Tools                      Functional annotation                                                                                                   Link                                                References
  -------------------------- ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------
  LincSNP 2.0                Store and annotate disease-associated SNVs in human lncRNAs and their transcription factor binding sites (TFBSs)        <http://bioinfo.hrbmu.edu.cn/LincSNP>               [@B68]
  lncRNASNP2                 Comprehensive information of SNVs and mutations in lncRNAs, as well as their impacts on lncRNA structure and function   <http://bioinfo.life.hust.edu.cn/lncRNASNP2>        [@B65]
  LncVar                     A database of genetic variation associated with long non-coding genes in six species                                    <http://bioinfo.ibp.ac.cn/LncVar>                   [@B6]
  The 1000 Genomes Project   The largest public catalog of human variation and genotype data                                                         <http://www.internationalgenome.org/>               [@B21]
  dbSNP                      A public-domain archive for a broad collection of simple genetic polymorphisms                                          <https://www.ncbi.nlm.nih.gov/snp>                  
  GWAS Catalog               A catalog that has provided data from published genome-wide association studies                                         [www.ebi.ac.uk/gwas/](http://www.ebi.ac.uk/gwas/)   [@B61]
  GWAS4D                     A web server that systematically evaluates GWAS signals and identifies context-specific regulatory variants             <http://mulinlab.tmu.edu.cn/gwas4d>                 [@B39]

SNVs, single-nucleotide variants; lncRNAs, long non-coding RNAs; GWAS, genome-wide association study.

Functional annotations and linkage disequilibrium analyses of genetic variants can be performed based on public databases and bioinformatic methods. Among tag-SNVs with strong linkage disequilibrium, significant genotype-specific effects on lincRNA expression can be observed by eQTL analysis ([@B26]). Subsequently, according to ChIP-Seq data from the ENCODE database^[1](#footnote1){ref-type="fn"}^, some trait-associated SNVs can be picked out; those variants mapping to *cis*-regulatory motifs may affect the binding activities of many interrelated transcription factors, including EZH2, CHD1, TCF7L2, and CTCF. These transcription factors may be closely related to the occurrence and progression of various human disorders, such as enhancer of zeste homologue 2 (EZH2), which is overexpressed in several human tumors and accounts for the aggressiveness and unfavorable prognoses of various cancers.

Function Verification {#S6.SS2}
---------------------

Many functional verification studies of genetic variants have focused on protein-coding regions of the human genome. With an expanding appreciation that non-coding variants play a crucial role in the development of disorders, several recent studies have set out to explore approaches to evaluate the function of non-coding variants ([@B46]). For example, experimental methods used to understand the effects of *cis*-regulatory variants within a promoter or enhancer region on cellular biological functions is summarized as follows. A main strategy is required to introduce the sequence variants, the mutated DNA fragment can be constructed *via* site-directed mutagenesis, CRISPR--Cas system ([@B49]) or oligonucleotide synthesis. Subsequently, the functional output of non-coding variants should be detected through several methods, either luciferase reporter assays or high-throughput sequencing-based assays, such as *cis*-regulatory element analysis by sequencing (CRE-seq) ([@B52]) and self-transcribing active regulatory region sequencing (STARR-seq) ([@B2]). Furthermore, functional verification is required to determine the direct biological significances, such as the oncogenic properties, which can be manifested though cancer cellular experiments (e.g., cell proliferation, cell cycle, cell death, migration, and invasion tests) along with *in vivo* model assays. In addition, other approaches are needed to be explored to demonstrate the effects of genetic variants within introns, exons, or intergenic regions. For instance, genetic variants mapping to exons of a lincRNA may alter the lincRNA secondary structure, which can be partly predicted using RNAfold web server ([@B35]). The 5′ UTR (un-translated region) variants may affect the process of splicing and stability of RNA conformation, a functional splicing reporter minigene assay should be used to assess the effect of genetic variants on RNA splicing ([@B24]). Through the aforementioned knowable strategies, comprehensive functional verification of non-coding variants is very important to understand their biological consequence; there is an urgent need to explore more practical methods and strategies for functional verification research.

Perspectives and Discussion {#S7}
===========================

Single-nucleotide variants are the most common genetic variants and universally present in the human genome, including non-coding regions. One current belief is that heterogeneous disease (e.g., cancers susceptibility) may be caused by the accumulation of multiple driving genetic variations. GWASs have identified a large number of disease or trait-associated SNVs, and many of those are located in non-coding regions of the human genome. The functions of genetic variants are generally unknown and remain to be elucidated. One critical common viewpoint is that the significance of lincRNA variants depends on their genomic position. Certain SNVs are located in regulatory regions of lincRNA genes; it is found to affect the binding efficiency of transcription factor; it is known to possibly regulate the transcription of lincRNAs and other related genes in a cell-type- or tissue-specific manner. The mapping of SNVs to lincRNA transcript itself potentially affects the process of splicing and stability of lincRNA conformation or modulates the lincRNA secondary structure; these effects may lead to an alteration of the interactive properties and regulatory functions of lincRNA ([@B46]). Collectively, these findings indicate that genetic variants in lincRNA regions may serve as a regulatory signature for early events, which illustrate the genomic background of lincRNA differential expressions in a tissue- or disorder-specific manner.

Considering their important regulatory role, lincRNAs may serve as the promising biomarkers for the diagnosis, prognosis, and treatment response of various diseases ([@B106]). With their characteristic of tissue and disease specificity, lincRNAs may be explored as target molecules for personalized medicine in the future ([@B40]). Currently, molecular targets drug approved by the US Food and Drug Administration (FDA) are mainly derived from proteins. However, owing to the finiteness of druggable protein genes in the human genome, the expansion of potentially druggable targets may need to include lncRNA molecules. One lincRNA *PCA3*-based test (the PROGENSA *PCA3* assay approved by the FDA) has been used as a marker for the detection of prostate cancers ([@B14]). Moreover, a novel treatment strategy differs from the classical small molecules and antibodies that mainly target proteins. RNA-targeting therapeutics refer to the use of oligonucleotides to target primarily RNA involved in various diseases for therapeutic efforts. Two major approaches are employed to target RNA: double-stranded RNA-mediated interference (RNAi) and antisense oligonucleotides (ASOs) ([@B48]). Currently, both methods are in clinical trials. Among them, nusinersen (Spinraza), an ASO-targeting drug for spinal muscular atrophy (SMA), has been approved by the FDA ([@B16]); patisiran, an RNAi therapeutic strategy for hereditary transthyretin amyloidosis (hATTR), has also shown promising results ([@B1]). Hence, we can expect that lincRNA molecules will provide additional options for RNA therapeutics. Importantly, disease-associated variants are found to exhibit a higher frequency in non-coding regions, which encompass enhancers, promoters, and other regulatory elements. It is likely that the role of genetic variants in lincRNA regions should be characterized at the regulatory network level. Genetic variants may offer the possibility to make use of the information from adjacent protein-coding or non-coding regions to link with heterogeneous diseases. Therefore, a combination of SNVs, lincRNAs, and proteins may bring personalized medicine closer to clinical applications in the foreseeable future ([@B54]).

Previous studies may appear to be a slightly biased against the genetic variants that are located in non-coding regions, as their significant roles have not yet been explored to the same extent as those of protein-coding genes. In particular, for the disease-associated variants in lincRNA regions, whether functionally affected or altered in lincRNA expression by risk variants, it may be responsible for the disease development and its pathogenesis. Verification of the mechanisms requires a detailed understanding of the lincRNA structure and function, and a suitable experimental system to distinguish the subtle differences caused by genetic variants. Although it is difficult to describe the consequences of genetic variants in non-coding regions, more emerging technologies and approaches are urgently needed to explore the driving effects of genetic variants on lincRNA regions.
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